Europe: Food, Drugs, Healthcare, Life Sciences

Takviye edici gıdalarda taklit ve tağşiş fiilleri, gıda mevzuatına aykırılık oluşturmanın ötesinde cezai, idari ve özel hukuk sorumluluğu doğurabilir. Bu makale, takviyelere ilişkin mevzuat çerçevesini, taklit ve tağşiş ayrımını, uygulanabilecek yaptırımları ve Yargıtay kararlarını inceleyerek ürün güvenilirliği, tüketici sağl

Bosnia and Herzegovina's new Patent Law introduces the utility model as a replacement for consensual patents, restructures the relationship with the European patent system, and establishes a more detailed framework for supplementary protection certificates. These changes will require manufacturers, pharmaceutical companies, and rights holders to reassess their intellectual property strategies before the law takes effect in June 2027.

Turkey's pharmaceutical regulatory landscape has evolved with new naming guidelines for human medicinal products. The Turkish Medicines and Medical Devices Agency has established comprehensive procedures for assessing product name similarity, incorporating INN root analysis and automated screening systems. These regulations introduce structured evaluation criteria and appeal mechanisms that will reshape how pharmaceutical companies approach product naming in the Turkish market.

Geopolitical conflicts and climate change are threatening global food security by disrupting fertiliser supply chains and driving up costs. European companies are developing innovative solutions ranging from green ammonia production and nitrogen fixation technologies to circular fertilisers derived from waste streams and biological alternatives that enhance nutrient efficiency.

Glasgow's XWORKS innovation hub represents a £11 million investment in advanced manufacturing infrastructure, set to provide 45,000 sq ft of flexible workspace for mid-tech companies in clean energy, defence, space and life sciences sectors. The facility, scheduled for completion in early 2027, aims to lift technological limitations for innovators and start-ups while strengthening Glasgow's position as a destination for innovation-led businesses.

Having entered yet another year with renewed optimism, the first half of 2026 did not fail to deliver. Deal volume and overall value are both going strong and, if this momentum continues, 2026 is on track to be one of the best for deal activity the sector for a number of years.

The NHS’s plan for 250 neighbourhood health centres hinges on private investment but, as Jennifer Lewis, real estate partner at Mills & Reeve, argues, unlocking strong investor appetite will require a more commercially viable model and a clearer route through the system.

Women’s healthcare in England faces significant challenges. There are a range of services provided by the NHS to women including gynaecology, obstetrics, contraception and reproductive health however they face several issues including increased waiting times, resulting in delayed diagnoses and treatment, and limited funding.

Healthcare providers delivering medical services at sporting and cultural events face a significant regulatory shift as new amendments remove longstanding exemptions from Care Quality Commission registration. The changes, stemming from recommendations in the Manchester Arena Inquiry, will require many event healthcare providers to register with the CQC for the first time, fundamentally altering how medical services at festivals, concerts, and sporting fixtures are regulated.